Recent developments have resolved frictions surrounding data usage in opioid use disorder research, leading to a low-risk posture. The clarification that analyses relied on IRB-approved, de-identified data aligns with privacy regulations, distinguishing them from restrictions on identifiable reproductive records. This reconciliation supports robust findings using DNA methylation that predict opioid use disorder, enhancing opportunities for early diagnosis and targeted treatments.
“ILCs are a family of innate lymphocytes, categorized as ILC1s, ILC2s, and ILC3s.”
“The results of this study revealed that ILCPs segregate into two distinct clusters on the basis of unique DNA methylation features.”
“Kang, L., Sonnenberg, G.F. Epigenetics control lineage decisions during hematopoiesis of innate lymphocytes.”
“The combined MRS and hMRS explained 34.5% of the variance in OUD.”
“We demonstrated that these two epigenetic marks are functionally distinct and can exhibit different gene regulatory processes.”
“OUD affects over 16 million people worldwide and is associated with increased health risks and morbidity.”
“We observed a higher prediction ability for hMRS (AUC = 0.862) than MRS (AUC = 0.718).”
“OUD was significantly associated with both MRS (β = 0.757, p = 0.0331) and hMRS (β = 0.845, p = 0.0001).”
“OUD was significantly associated with both MRS (β = 0.757, p = 0.0331) and hMRS (β = 0.845, p = 0.0001).”
“the combination of the covariates with hMRS (p = 0.00014) and the combination of the covariates with MRS and hMRS (p = 0.00014) resulted in an explained variance of 42%.”
“Our findings indicate that hMRS outperforms MRS at predicting OUD.”
“We show that hMRS outperforms MRS in the prediction accuracy of OUD.”